share_log

Baird Initiates Coverage On Bright Minds Biosciences With Outperform Rating, Announces Price Target of $75

Benzinga ·  Nov 26, 2024 05:21  · Ratings

Baird analyst Joel Beatty initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $75.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment